- Home
- NPT vs PLRX Comparison
NPT vs PLRX Comparison
Compare NPT & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NPT | PLRX |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.3M | 73.7M |
| IPO Year | 2024 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NPT | PLRX |
|---|---|---|
| Price | $2.80 | $1.13 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | 14.6K | ★ 364.4K |
| Earning Date | 05-23-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.14 | $1.02 |
| 52 Week High | $22.38 | $1.95 |
Technical Indicators
Market Signals| Indicator | NPT | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 36.95 | 53.12 |
| Support Level | $2.31 | $1.11 |
| Resistance Level | $3.21 | $1.26 |
| Average True Range (ATR) | 0.22 | 0.04 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 11.90 | 61.87 |
Price Performance
Historical ComparisonAbout NPT Texxon Holding Limited Ordinary shares
Texxon Holding Ltd provides technology-enabled supply chain management services to customers in the plastics and chemical industries in East China. The company operates through two segments: Supply Chain Trading and Plastic Manufacturing. Its services include procurement, logistics, payments, and fulfillment for Chinese SMEs, and all revenue is generated from operations within the People's Republic of China.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.